



## Viral Hepatitis and Hepatocellular Carcinoma

Guest Editor:

**Dr. Ruchi Shukla**

Biosciences Institute, Newcastle  
University, Newcastle upon Tyne  
NE2 4HH, UK

Deadline for manuscript  
submissions:

**closed (31 August 2021)**

### Message from the Guest Editor

Dear Colleagues,

‘Viral hepatitis’ is a broad term to describe liver damage due to hepatitis virus (A, B, C, D and E) infection. Chronic hepatitis can lead to complications such as cirrhosis, liver failure and liver cancer, especially hepatocellular carcinoma (HCC).

Hepatitis B and C virus (HBV and HCV) infections are leading cause of HCC worldwide. A safe and effective vaccine against HBV is now available. There is no vaccine for HCV however, a major advance in the liver field in last 5 years has been the introduction of direct acting antivirals (DAAs) targeting HCV infection.

HCC is a stepwise process and involves a combination of genetic and epigenetic alterations. Hence, in this special issue I invite you to submit original articles, case reports or review articles to advance our existing knowledgebase regarding (i) viral hepatitis prevention or treatment, (ii) screening of chronic hepatitis patients to assess HCC development, (iii) molecular pathogenesis of viral hepatitis-related HCC development and (iv) novel treatment strategies for viral hepatitis-related HCC.

Dr. Ruchi Shukla  
Guest Editor





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)